PROVIREX is focused on developing a modular gene therapy platform to target retroviruses like HTLV-1.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| €1.7 M | Jul, 2025 | unspecified |
Industries
Frequently Asked Questions
What industries does PROVIREX Genome Editing Therapies GmbH operate in?
PROVIREX Genome Editing Therapies GmbH operates in the following industries: biotechnology, gene therapy, healthcare.
When was PROVIREX Genome Editing Therapies GmbH founded?
PROVIREX Genome Editing Therapies GmbH was founded on 2019-10-01.
How much total funding has PROVIREX Genome Editing Therapies GmbH raised?
PROVIREX Genome Editing Therapies GmbH has raised a total of $1,700,000.
Who are the investors in PROVIREX Genome Editing Therapies GmbH?
The investors in PROVIREX Genome Editing Therapies GmbH are: BIOVENTURE Consulting GmbH, IFB Hamburg.
Who are the founders of PROVIREX Genome Editing Therapies GmbH?
The founders of PROVIREX Genome Editing Therapies GmbH are: Dr. Niklas Beschorner, Dr. Dr. Ulrike Lange.